Essential papers: Difference between revisions

From DISI
Jump to navigation Jump to search
(Added docking theory papers)
m (Added to-do topics.)
Line 10: Line 10:


Discussion of general purpose concerns with regards to virtual screening, and guidelines for ensuring adequate control calculations. An incredibly useful resource. See also the Supplementary Information, which provides explanation for each row found in an INDOCK file (one of the core input files for DOCK 3.x).
Discussion of general purpose concerns with regards to virtual screening, and guidelines for ensuring adequate control calculations. An incredibly useful resource. See also the Supplementary Information, which provides explanation for each row found in an INDOCK file (one of the core input files for DOCK 3.x).
'''A paper on ZINC, whether the original, ZINC16, ZINC20, ZINC22, or another''' -- tbd which one
'''A paper on DUD / DUD-E / DUD-EZ''' -- tbd which one


'''The impact of library size and scale on virtual screening''' -- [https://doi.org/10.1038/s41589-024-01797-w Nature Chem Bio (2025)]
'''The impact of library size and scale on virtual screening''' -- [https://doi.org/10.1038/s41589-024-01797-w Nature Chem Bio (2025)]
Line 42: Line 46:


What changes are most likely to improve the activity of a small molecule? And, how do we know whether a new method is better than random chance? This work sets out to establish a baseline for comparison, and provide insight into what modifications prove most useful for a given goal (increased potency, better PK, etc).
What changes are most likely to improve the activity of a small molecule? And, how do we know whether a new method is better than random chance? This work sets out to establish a baseline for comparison, and provide insight into what modifications prove most useful for a given goal (increased potency, better PK, etc).
'''A paper on SEA''' -- Keiser has 2 separate papers, Maya will have her own coming out soon(ish?). Which one?
'''A paper on aggregates''' -- 2002 JMed Chem?
'''A paper on PAINS''' -- Maybe a better reference than our labs aggregate paper, at least from the perspective of introducing the general concept of 'chemotypes that cause problems'. I forget which of Baell's papers is most well-known.


[[Category:Papers]]
[[Category:Papers]]

Revision as of 19:51, 20 October 2026

The papers here are not exhaustive by any means, but are meant to serve as references for new members of the lab. Feel free to add additional papers here; alternatively, consider adding more specialized papers or applications of DOCK to Classic Dock References or Greatest Hits respectively.

On using DOCK for virtual screening

Read the dock docs -- Available here

The dock docs contain everything you need to know about running DOCK on our clusters, including commands that you can copy/paste in your own work. Functionally, our standard operating procedures for docking.

A practical guide to large-scale docking -- Nature Protocols (2021)

Discussion of general purpose concerns with regards to virtual screening, and guidelines for ensuring adequate control calculations. An incredibly useful resource. See also the Supplementary Information, which provides explanation for each row found in an INDOCK file (one of the core input files for DOCK 3.x).

A paper on ZINC, whether the original, ZINC16, ZINC20, ZINC22, or another -- tbd which one

A paper on DUD / DUD-E / DUD-EZ -- tbd which one

The impact of library size and scale on virtual screening -- Nature Chem Bio (2025)

Bigger is better, and this paper demonstrates that screening larger libraries increases the likelihood of finding high-affinity hits. Just as importantly, this paper looks at how many compounds must be purchased/tested in order to reliably determine the hit rate from a given screen.

On how DOCK works (theory)

Automated docking with grid-based energy evaluation -- J Comput Chem (1992)

How DOCK scores molecules. Rather than calculating every protein-ligand interaction from scratch, protein contribution to interaction energies (van der Waals, electrostatics, desolvation) are precomputed on a grid to be independent of ligands (by approximating), then when docking, the ligand atoms simply look up protein contribution to energies at the nearest grid points. This trick allows docking to be fast enough to screen at the scales we do. This paper does not include desolvation, as it was added later in. Speaking of!

Rapid context-dependent ligand desolvation in molecular docking -- J Chem Inf Model (2010)

Explains how DOCK accounts for energetic penalty of stripping water away from a ligand as it binds. Full water to octanol desolvation energetic penalty (so-called full transfer desolvation) of each atom is pre-computed at ligand building stage. Then at docking time, instead of applying a flat penalty, each ligand atom's desolvation cost is a fraction of the full transfer cost, scaled by how buried it is in the binding site. So, a polar group out in solvent is penalized less than one buried in a hydrophobic pocket.

Ligand pose and orientational sampling in molecular docking -- PLoS One (2013)

How DOCK places our pre-built ligand conformers into protein pocket. It is a deterministic (non-random, repeatable) algorithm that given a set of user defined "matching spheres" that dot the protein surface, the algorithm finds possible ligand pocket placements by matching internal distances of the protein matching spheres (protein pocket curvature shape) to the internal distances in ligand's rigid fragment atoms (ligand shape).

On medicinal chemistry

A medicinal chemist's guide to molecular interactions -- J Med Chem (2010)

This is an exhaustive guide towards reviewing the interaction of small molecules with proteins. Especially useful are the discussion of ideal bond lengths, angles, and energies. A must-read before (and during... and after... tbh just read this every few months) hit-picking from a virtual screen.

A Real-World Perspective on Molecular Design -- J Med Chem (2016)

A good read after "A medicinal chemist's guide to molecular interactions". The paper is full of real-world strategies, problems, and surprises in ligand optimization. All examples are based on prospective computational drug design. Especially helpful to read before analoging your hit series.

Development of a random background to understand ligand optimization -- Nature (2026)

What changes are most likely to improve the activity of a small molecule? And, how do we know whether a new method is better than random chance? This work sets out to establish a baseline for comparison, and provide insight into what modifications prove most useful for a given goal (increased potency, better PK, etc).

A paper on SEA -- Keiser has 2 separate papers, Maya will have her own coming out soon(ish?). Which one?

A paper on aggregates -- 2002 JMed Chem?

A paper on PAINS -- Maybe a better reference than our labs aggregate paper, at least from the perspective of introducing the general concept of 'chemotypes that cause problems'. I forget which of Baell's papers is most well-known.